Diabetes drug may reduce heart attack risk in HIV patients

Diabetes drug may reduce heart attack risk in HIV patients
Researchers at Washington University School of Medicine in St. Louis found that the diabetes drug sitagliptin (brand name Januvia) improved glucose metabolism and reduced inflammation in HIV-positive adults on antiretroviral therapy, suggesting that the drug may lower risk of heart attacks and strokes. Credit: E. Holland Durando

In patients with HIV, a diabetes drug may have benefits beyond lowering blood sugar. A new study from researchers at Washington University School of Medicine in St. Louis suggests the drug may prevent cardiovascular problems because it works to reduce inflammation linked to heart disease and stroke in these patients.

Although infection with is no longer a , people with the virus have an elevated risk of heart attacks and diabetes, and problems with glucose, insulin and cholesterol. Part of what drives that risk is .

In the new study, the researchers found that the sitagliptin (brand name Januvia) both improved metabolism and reduced inflammation in HIV-positive adults taking antiretroviral therapy. The findings are published in The Journal of Clinical Endocrinology & Metabolism.

"The goal has been to identify treatments that not only address problems with blood sugar and lipids but also can lower inflammation, which can play a substantial role in and stroke," said principal investigator Kevin E. Yarasheski, PhD, a professor of medicine. "With sitagliptin, sugar levels fell, and several markers of immune activation and inflammation were reduced, indicating the drug may provide long-term benefits for these patients' hearts, bones and livers."

Yarasheski explained that standard diabetes therapies have been tried in HIV patients and have been somewhat successful but do not completely normalize blood sugar, insulin and lipid levels, and other indicators of heart and metabolic health.

Researchers at washington university school of medicine in St. Louis have found that a diabetes drug appears to lower cardiovascular risk and more effectively treat glucose problems in people with HIV. Jim Dryden reports. Credit: Washington University BioMed Radio

The new, eight-week study of sitagliptin was the second study of the drug in people with HIV. The first, which also was conducted by Yarasheski's team, involved 20 patients and focused on whether sitagliptin was safe. This time, researchers wanted see whether the drug provided specific health benefits.

They studied 36 HIV patients, ages 18-65, who were on antiretroviral therapy and whose immune status was stable. At the start of the study, the researchers measured subjects' glucose levels, insulin sensitivity, lipid levels, immune cell counts, several markers of inflammation and other indicators of health. Identifying treatments for these patients can be difficult, mainly because of potential interactions with HIV drugs patients take to keep the infection from becoming AIDS.

Half of the study subjects then took sitagliptin for eight weeks, and the others received a placebo. Meanwhile, everyone in the study continued with .

"We wanted to know whether this drug would improve patients' blood-sugar problems and reduce the immune markers that we believe are indicators that something is activating the immune system and causing inflammation," Yarasheski said. "And that's what we found."

Longer-term studies are needed to learn whether lower markers of inflammation after eight weeks of treatment can lead to lower risk for heart attacks and metabolic problems, but the preliminary signs are promising, said Yarasheski, also a professor of cell biology and physiology and of physical therapy.

"Lowering isn't enough," he said. "Just treating lipids isn't enough. We want to target the nexus between metabolic regulation and immune regulation. Whether this particular drug lowers inflammation enough to actually reduce cardiovascular disease, , stroke and hypertension is a question that still needs to be addressed. But these findings are a step in the right direction."

Explore further

Diabetes drug safe for HIV patients, study finds

More information: Best C, Struthers H, Laciny E, Royal M, Reeds DN, Yarasheski KE. Sitagliptin reduces inflammation and chronic immune cell activation in HIV+ adults with impaired glucose tolerance. The Journal of Clinical Endocrinology & Metabolism, published online May 4, 2015; dx.doi.org/10.1210/jc.2015-1531
Citation: Diabetes drug may reduce heart attack risk in HIV patients (2015, May 14) retrieved 13 December 2019 from https://medicalxpress.com/news/2015-05-diabetes-drug-heart-hiv-patients.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments